Long-term efficacy and therapeutic drug monitoring of sertraline in major depression
Maintenance treatment for depression should be considered as a chronic disease management programme. Several studies have reported that sertraline (SRT) can be useful in preventing relapses and recurrent episodes of major depression. Twenty‐three outpatients, 14 males and 9 females, affected by majo...
Gespeichert in:
Veröffentlicht in: | Human psychopharmacology 2003-07, Vol.18 (5), p.385-388 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 388 |
---|---|
container_issue | 5 |
container_start_page | 385 |
container_title | Human psychopharmacology |
container_volume | 18 |
creator | Mauri, Massimo C. Fiorentini, Alessio Cerveri, Giancarlo Volonteri, Lucia S. Regispani, Francesca Malvini, Lara Boscati, Luigi Baido, Rosita Lo Invernizzi, Giordano |
description | Maintenance treatment for depression should be considered as a chronic disease management programme. Several studies have reported that sertraline (SRT) can be useful in preventing relapses and recurrent episodes of major depression.
Twenty‐three outpatients, 14 males and 9 females, affected by major depressive disorder, recurrent (DSM‐IV criteria) were included. The patients were prescribed 25–150 mg of SRT for 12 months and were evaluated at baseline (T0), after 15 days (T0.5), 30 days (T1), 6 months (T6) and 12 months (T12) by using the brief psychiatric rating scale (BPRS), Hamilton rating scale for anxiety (HRS‐A) and Hamilton rating scale for depression (HRS‐D). Plasma samples for SRT level determination were collected at T0.5, T1, T6 and T12. There was a positive relationship between SRT oral dose and drug plasma levels. Lower plasma levels, 25–50 ng/ml, were adequate for clinical maintenance treatment.
Our data suggest that SRT seems to be effective and well tolerated at low dosages both in the acute and maintenance treatment of recurrent depression. Monitoring the SRT plasma level, even though not strictly necessary from a clinical point of view, can be useful in optimizing treatment. Copyright © 2003 John Wiley & Sons, Ltd. |
doi_str_mv | 10.1002/hup.502 |
format | Article |
fullrecord | <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_hup_502</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>HUP502</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3512-18b36c2c7dca9ea0d03df9b82a3bc21b2097dd6f58581a5f3c78bc147b9165cc3</originalsourceid><addsrcrecordid>eNp10MtKAzEYhuEgiq0HvAPJzoVMzcFMMkst2gpFrbQU3IRMDm1q50AyRXv3jkzRlass8vDx8wJwgdEAI0RuVtt6wBA5AH2MsizBiPND0EdCsCQlhPTASYxrhNo_lB2DHiaCCUrSPphNqnKZNDYU0DrntdI7qEoDm5UNqrbbxmtownYJi6r0TRV8uYSVg9GGJqiNLy30JSzUugrQ2DrYGH1VnoEjpzbRnu_fUzB_fJgNx8nkZfQ0vJskmjJMEixymmqiudEqswoZRI3LckEUzTXBOUEZNyZ1rD0WK-ao5iLX-JbnGU6Z1vQUXHW7OlQxButkHXyhwk5iJH-6yLaLbLu08rKT9TYvrPlz-xAtuO7Ap9_Y3X87cjx_7eaSTvvY2K9frcKHTDnlTC6eR_L9fvEmhtORnNJvYNd8eQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Long-term efficacy and therapeutic drug monitoring of sertraline in major depression</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>Mauri, Massimo C. ; Fiorentini, Alessio ; Cerveri, Giancarlo ; Volonteri, Lucia S. ; Regispani, Francesca ; Malvini, Lara ; Boscati, Luigi ; Baido, Rosita Lo ; Invernizzi, Giordano</creator><creatorcontrib>Mauri, Massimo C. ; Fiorentini, Alessio ; Cerveri, Giancarlo ; Volonteri, Lucia S. ; Regispani, Francesca ; Malvini, Lara ; Boscati, Luigi ; Baido, Rosita Lo ; Invernizzi, Giordano</creatorcontrib><description>Maintenance treatment for depression should be considered as a chronic disease management programme. Several studies have reported that sertraline (SRT) can be useful in preventing relapses and recurrent episodes of major depression.
Twenty‐three outpatients, 14 males and 9 females, affected by major depressive disorder, recurrent (DSM‐IV criteria) were included. The patients were prescribed 25–150 mg of SRT for 12 months and were evaluated at baseline (T0), after 15 days (T0.5), 30 days (T1), 6 months (T6) and 12 months (T12) by using the brief psychiatric rating scale (BPRS), Hamilton rating scale for anxiety (HRS‐A) and Hamilton rating scale for depression (HRS‐D). Plasma samples for SRT level determination were collected at T0.5, T1, T6 and T12. There was a positive relationship between SRT oral dose and drug plasma levels. Lower plasma levels, 25–50 ng/ml, were adequate for clinical maintenance treatment.
Our data suggest that SRT seems to be effective and well tolerated at low dosages both in the acute and maintenance treatment of recurrent depression. Monitoring the SRT plasma level, even though not strictly necessary from a clinical point of view, can be useful in optimizing treatment. Copyright © 2003 John Wiley & Sons, Ltd.</description><identifier>ISSN: 0885-6222</identifier><identifier>EISSN: 1099-1077</identifier><identifier>DOI: 10.1002/hup.502</identifier><identifier>PMID: 12858326</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Adult ; Aged ; Depressive Disorder, Major - drug therapy ; Dose-Response Relationship, Drug ; Drug Monitoring ; Female ; Humans ; long term efficacy ; major depression ; Male ; Middle Aged ; plasma levels ; prophylaxis ; Prospective Studies ; Psychiatric Status Rating Scales ; Serotonin Uptake Inhibitors - adverse effects ; Serotonin Uptake Inhibitors - blood ; Serotonin Uptake Inhibitors - therapeutic use ; sertraline ; Sertraline - adverse effects ; Sertraline - blood ; Sertraline - therapeutic use ; Time Factors</subject><ispartof>Human psychopharmacology, 2003-07, Vol.18 (5), p.385-388</ispartof><rights>Copyright © 2003 John Wiley & Sons, Ltd.</rights><rights>Copyright 2003 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3512-18b36c2c7dca9ea0d03df9b82a3bc21b2097dd6f58581a5f3c78bc147b9165cc3</citedby><cites>FETCH-LOGICAL-c3512-18b36c2c7dca9ea0d03df9b82a3bc21b2097dd6f58581a5f3c78bc147b9165cc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhup.502$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhup.502$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12858326$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mauri, Massimo C.</creatorcontrib><creatorcontrib>Fiorentini, Alessio</creatorcontrib><creatorcontrib>Cerveri, Giancarlo</creatorcontrib><creatorcontrib>Volonteri, Lucia S.</creatorcontrib><creatorcontrib>Regispani, Francesca</creatorcontrib><creatorcontrib>Malvini, Lara</creatorcontrib><creatorcontrib>Boscati, Luigi</creatorcontrib><creatorcontrib>Baido, Rosita Lo</creatorcontrib><creatorcontrib>Invernizzi, Giordano</creatorcontrib><title>Long-term efficacy and therapeutic drug monitoring of sertraline in major depression</title><title>Human psychopharmacology</title><addtitle>Hum. Psychopharmacol. Clin. Exp</addtitle><description>Maintenance treatment for depression should be considered as a chronic disease management programme. Several studies have reported that sertraline (SRT) can be useful in preventing relapses and recurrent episodes of major depression.
Twenty‐three outpatients, 14 males and 9 females, affected by major depressive disorder, recurrent (DSM‐IV criteria) were included. The patients were prescribed 25–150 mg of SRT for 12 months and were evaluated at baseline (T0), after 15 days (T0.5), 30 days (T1), 6 months (T6) and 12 months (T12) by using the brief psychiatric rating scale (BPRS), Hamilton rating scale for anxiety (HRS‐A) and Hamilton rating scale for depression (HRS‐D). Plasma samples for SRT level determination were collected at T0.5, T1, T6 and T12. There was a positive relationship between SRT oral dose and drug plasma levels. Lower plasma levels, 25–50 ng/ml, were adequate for clinical maintenance treatment.
Our data suggest that SRT seems to be effective and well tolerated at low dosages both in the acute and maintenance treatment of recurrent depression. Monitoring the SRT plasma level, even though not strictly necessary from a clinical point of view, can be useful in optimizing treatment. Copyright © 2003 John Wiley & Sons, Ltd.</description><subject>Adult</subject><subject>Aged</subject><subject>Depressive Disorder, Major - drug therapy</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Monitoring</subject><subject>Female</subject><subject>Humans</subject><subject>long term efficacy</subject><subject>major depression</subject><subject>Male</subject><subject>Middle Aged</subject><subject>plasma levels</subject><subject>prophylaxis</subject><subject>Prospective Studies</subject><subject>Psychiatric Status Rating Scales</subject><subject>Serotonin Uptake Inhibitors - adverse effects</subject><subject>Serotonin Uptake Inhibitors - blood</subject><subject>Serotonin Uptake Inhibitors - therapeutic use</subject><subject>sertraline</subject><subject>Sertraline - adverse effects</subject><subject>Sertraline - blood</subject><subject>Sertraline - therapeutic use</subject><subject>Time Factors</subject><issn>0885-6222</issn><issn>1099-1077</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10MtKAzEYhuEgiq0HvAPJzoVMzcFMMkst2gpFrbQU3IRMDm1q50AyRXv3jkzRlass8vDx8wJwgdEAI0RuVtt6wBA5AH2MsizBiPND0EdCsCQlhPTASYxrhNo_lB2DHiaCCUrSPphNqnKZNDYU0DrntdI7qEoDm5UNqrbbxmtownYJi6r0TRV8uYSVg9GGJqiNLy30JSzUugrQ2DrYGH1VnoEjpzbRnu_fUzB_fJgNx8nkZfQ0vJskmjJMEixymmqiudEqswoZRI3LckEUzTXBOUEZNyZ1rD0WK-ao5iLX-JbnGU6Z1vQUXHW7OlQxButkHXyhwk5iJH-6yLaLbLu08rKT9TYvrPlz-xAtuO7Ap9_Y3X87cjx_7eaSTvvY2K9frcKHTDnlTC6eR_L9fvEmhtORnNJvYNd8eQ</recordid><startdate>200307</startdate><enddate>200307</enddate><creator>Mauri, Massimo C.</creator><creator>Fiorentini, Alessio</creator><creator>Cerveri, Giancarlo</creator><creator>Volonteri, Lucia S.</creator><creator>Regispani, Francesca</creator><creator>Malvini, Lara</creator><creator>Boscati, Luigi</creator><creator>Baido, Rosita Lo</creator><creator>Invernizzi, Giordano</creator><general>John Wiley & Sons, Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>200307</creationdate><title>Long-term efficacy and therapeutic drug monitoring of sertraline in major depression</title><author>Mauri, Massimo C. ; Fiorentini, Alessio ; Cerveri, Giancarlo ; Volonteri, Lucia S. ; Regispani, Francesca ; Malvini, Lara ; Boscati, Luigi ; Baido, Rosita Lo ; Invernizzi, Giordano</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3512-18b36c2c7dca9ea0d03df9b82a3bc21b2097dd6f58581a5f3c78bc147b9165cc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Depressive Disorder, Major - drug therapy</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Monitoring</topic><topic>Female</topic><topic>Humans</topic><topic>long term efficacy</topic><topic>major depression</topic><topic>Male</topic><topic>Middle Aged</topic><topic>plasma levels</topic><topic>prophylaxis</topic><topic>Prospective Studies</topic><topic>Psychiatric Status Rating Scales</topic><topic>Serotonin Uptake Inhibitors - adverse effects</topic><topic>Serotonin Uptake Inhibitors - blood</topic><topic>Serotonin Uptake Inhibitors - therapeutic use</topic><topic>sertraline</topic><topic>Sertraline - adverse effects</topic><topic>Sertraline - blood</topic><topic>Sertraline - therapeutic use</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mauri, Massimo C.</creatorcontrib><creatorcontrib>Fiorentini, Alessio</creatorcontrib><creatorcontrib>Cerveri, Giancarlo</creatorcontrib><creatorcontrib>Volonteri, Lucia S.</creatorcontrib><creatorcontrib>Regispani, Francesca</creatorcontrib><creatorcontrib>Malvini, Lara</creatorcontrib><creatorcontrib>Boscati, Luigi</creatorcontrib><creatorcontrib>Baido, Rosita Lo</creatorcontrib><creatorcontrib>Invernizzi, Giordano</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Human psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mauri, Massimo C.</au><au>Fiorentini, Alessio</au><au>Cerveri, Giancarlo</au><au>Volonteri, Lucia S.</au><au>Regispani, Francesca</au><au>Malvini, Lara</au><au>Boscati, Luigi</au><au>Baido, Rosita Lo</au><au>Invernizzi, Giordano</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term efficacy and therapeutic drug monitoring of sertraline in major depression</atitle><jtitle>Human psychopharmacology</jtitle><addtitle>Hum. Psychopharmacol. Clin. Exp</addtitle><date>2003-07</date><risdate>2003</risdate><volume>18</volume><issue>5</issue><spage>385</spage><epage>388</epage><pages>385-388</pages><issn>0885-6222</issn><eissn>1099-1077</eissn><abstract>Maintenance treatment for depression should be considered as a chronic disease management programme. Several studies have reported that sertraline (SRT) can be useful in preventing relapses and recurrent episodes of major depression.
Twenty‐three outpatients, 14 males and 9 females, affected by major depressive disorder, recurrent (DSM‐IV criteria) were included. The patients were prescribed 25–150 mg of SRT for 12 months and were evaluated at baseline (T0), after 15 days (T0.5), 30 days (T1), 6 months (T6) and 12 months (T12) by using the brief psychiatric rating scale (BPRS), Hamilton rating scale for anxiety (HRS‐A) and Hamilton rating scale for depression (HRS‐D). Plasma samples for SRT level determination were collected at T0.5, T1, T6 and T12. There was a positive relationship between SRT oral dose and drug plasma levels. Lower plasma levels, 25–50 ng/ml, were adequate for clinical maintenance treatment.
Our data suggest that SRT seems to be effective and well tolerated at low dosages both in the acute and maintenance treatment of recurrent depression. Monitoring the SRT plasma level, even though not strictly necessary from a clinical point of view, can be useful in optimizing treatment. Copyright © 2003 John Wiley & Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>12858326</pmid><doi>10.1002/hup.502</doi><tpages>4</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0885-6222 |
ispartof | Human psychopharmacology, 2003-07, Vol.18 (5), p.385-388 |
issn | 0885-6222 1099-1077 |
language | eng |
recordid | cdi_crossref_primary_10_1002_hup_502 |
source | Wiley Online Library - AutoHoldings Journals; MEDLINE |
subjects | Adult Aged Depressive Disorder, Major - drug therapy Dose-Response Relationship, Drug Drug Monitoring Female Humans long term efficacy major depression Male Middle Aged plasma levels prophylaxis Prospective Studies Psychiatric Status Rating Scales Serotonin Uptake Inhibitors - adverse effects Serotonin Uptake Inhibitors - blood Serotonin Uptake Inhibitors - therapeutic use sertraline Sertraline - adverse effects Sertraline - blood Sertraline - therapeutic use Time Factors |
title | Long-term efficacy and therapeutic drug monitoring of sertraline in major depression |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T12%3A50%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20efficacy%20and%20therapeutic%20drug%20monitoring%20of%20sertraline%20in%20major%20depression&rft.jtitle=Human%20psychopharmacology&rft.au=Mauri,%20Massimo%20C.&rft.date=2003-07&rft.volume=18&rft.issue=5&rft.spage=385&rft.epage=388&rft.pages=385-388&rft.issn=0885-6222&rft.eissn=1099-1077&rft_id=info:doi/10.1002/hup.502&rft_dat=%3Cwiley_cross%3EHUP502%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/12858326&rfr_iscdi=true |